It is reported that the scientific research team led by Fan Daidi broke through the scientific and technological research bottleneck of recombinant collagen and achieved success, which is known as the mother of “human-like collagen”.
Yesterday (July 10), “China’s first recombinant collagen stock” Giant Biogene released a personnel change, executive director Ms. Fan Daidi has submitted her resignation from her position as an executive director due to work arrangements, effective from July 7, 2023 onwards.
According to public information, Fan Daidi studied at the East China University of Science and Technology, Department of Bioengineering, and became China’s first female doctor of biochemistry. In 1994, at the age of 28, she returned to her alma mater. With 5,000 yuan of scientific research start-up funds, she began to research and development of human collagen. In 2000, breakthroughs in recombinant collagen science have been achieved and technological research bottlenecks have been solved. They achieved success. Its technology not only greatly overcome the drawbacks of animal collagen, but also the first Chinese independently developed. With independent intellectual property rights of the recombinant collagen, Fan Daidi is known as “human-like collagen” mother.
In the same year, she and her husband Yan Jianya set up Giant Biogene, which was listed on the Hong Kong Stock Exchange in November 2022, becoming “China’s first recombinant collagen stock”. According to the financial report of Giant Biogene in 2022, it realized operating revenue of 2.364 billion yuan ($328.2 million), up 52.3% year-on-year, and gross profit of 1.995 billion yuan ($277 million), up 47.3% year-on-year.
Currently, with years of research and development experience in biotechnology, synthetic biology technology and industry leadership, Giant Biogene has established a diversified product pipeline, including 49 efficacy skincare products, 37 medical dressings and four skin revitalization products under the brand portfolio of Kefumei and Collgene, as well as two biomedical products, seven health food products and three formulas for special medical purposes under the health portfolio of foods.
The two brands, Kefumei and Collegene, have also become Giant Biogene iconic brands. According to Giant Biogene financial report for 2022, revenue from Collgene was 618.4 million yuan ($85.8 million) in 2022, an increase of 17.6% compared to the same period in 2021. Revenue from Kefumei was 1.613 billion yuan ($223.9 million), a 79.7% jump compared to the same period in 2021.
NEWS, CHINESE BRANDS